Business
New poster presented at ASCP Meeting
New poster presented at ASCP Meeting.
About this update from Cellbxhealth Plc
[{"type":"text","content":"\n \n \n \n \n \n \n \n For immediate release\n \n \n \n \n \n \n 13 September 2022\n \n \n \n \n \n \n \n \n \n \n \n \n \n ANGLE plc (\"the Company\")\n \n \n \n \n \n \n \n ANGLE PRESENTS NEW POSTER AT AMERICAN SOCIETY FOR CLINICAL PATHOLOGY MEETING\n \n \n \n \n \n \n \n \n \n Poster describes novel use of Pap stain procedure to analyse morphology of CTCs harvested using the Parsortix system\n \n \n \n \n \n \n \n \n \n Approach could be easily implemented in standard pathology laboratory workflows\n \n \n \n \n \n \n ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company,\n is delighted to announce that its United States clinical laboratory team presented a new poster at the 100th American Society for Clinical Pathology (ASCP) meeting in Chicago, Illinois, USA between 7-9 September 2022. The poster, which describes the novel use of Papanicolaou (Pap) staining procedures with cells harvested from blood samples using the Parsortix® system, was selected as a finalist for a prestigious Blue Ribbon award for laboratory practice by ASCP judges.\n \n \n \n \n \n Pap staining is a polychromatic cytopathological staining technique used to differentiate cells in a sample and is most commonly used as a screening method for cervical cancer. In the experiments described in the poster, the ANGLE team used the technique to look at the morphology of metastatic malignant cells harvested by the Parsortix system, as a way of identifying CTCs. The team concluded that patient sample CTC analysis can be performed by combining the use of the Parsortix system with standard cytology staining and optimised analysis by qualified cytologists.\n \n \n \n \n \n Pap staining is a reliable and inexpensive technique used in pathology laboratories world-wide and ANGLE believes that when used with a Parsortix harvest, it could enable cytologists to quickly, and reliably, identify cells of interest. For example, circulating tumour cells (CTCs) identified in blood samples from cancer patients in remission could alert clinicians to the need for further investigation and testing.\n \n \n \n \n \n The poster is available\n online at\n \n \n https://angleplc.com/library/publications/\n \n \n .\n \n \n \n \n \n \n \n \n ANGLE Founder and Chief Executive, Andrew Newland, commented:\n \n \n \n \"As...